Elevated HDL2-paraoxonase and reduced CETP activity are associated with a dramatically lower ratio of LDL-cholesterol/total cholesterol in a hypercholesterolemic and hypertriglyceridemic patient

International Journal of Molecular Medicine

Volumn 25, Issue 6, 2010, Pages 945-951

  Lee, Ji Hye ^a   Park, Jung Heun ^a   Lee, Sang Hak ^b   Kim, Jae Ryong ^a   Cho, Kyung Hyun ^a  

^a Yeungnam University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Apolipoprotein A I; Cholesteryl ester transfer protein; Dyslipidemia; Paraoxonase

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ANTIOXIDANT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRON;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; OXIDATION; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; ENZYMOLOGY; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; ULTRASTRUCTURE; WESTERN BLOTTING;

ANTIOXIDANTS; APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; BLOTTING, WESTERN; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IRON; MIDDLE AGED; OXIDATION-REDUCTION;

EID: 77952756300     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm-00000426     Document Type: Article

References (30)

1. Grundy SM: Role of low-density lipoproteins in atherogenesis and development of coronary heart disease. Clin Chem 41: 139-146, 1995.
2. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL and Liao Y: Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52: 453-462, 2003.
3. Friedewald WT, Levy RI and Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972.
4. Rifai N, Warnick GR, McNamara JR, Belcher JD, Grinstead GF and Frantz ID Jr: Measurement of low-density-lipoprotein cholesterol in serum: a status report. Clin Chem 38: 150-160, 1992.
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. J Am Med Assoc 285: 2486-2497, 2001.
6. Cho KH: Biomedicinal implications of high-density lipoprotein: its composition, structure, functions, and clinical applications. BMB Rep 42: 393-400, 2009.
7. Gardner CD, Fortmann SP and Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. J Am Med Assoc 276: 875-881, 1996.
8. Fielding CJ and Fielding PE: Molecular physiology of reverse cholesterol transport. J Lipid Res 36: 211-228, 1995.
9. Havel RJ, Eder HA and Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353, 1995.
10. Markwell MA, Haas SM, Bieber LL and Tolbert NE: A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87: 206-210, 1978.
11. Blois MS: Antioxidant determination by the use of a stable free radicals. Nature 181: 1199 - 2000, 1958.
12. Esterbauer H, Striegl G, Puhl H and Rotheneder M: Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6: 67-75, 1989.
13. Noble RP: Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res 9: 693-700, 1968.
14. Benzie IF and Strain JJ: The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: the FRAP assay. Anal Biochem 239: 70-76, 1996.
15. Cho KH: Synthesis of reconstituted high density lipoprotein (rHDL) containing apoA-I and apoC-III: the functional role of apoC-III in rHDL. Mol Cells 27: 291-297, 2009.
16. Cho KH, Shin DG, Baek SH and Kim JR: Myocardial infarction patients showed altered lipoprotein properties and functions when compared with stable angina pectoris patients. Exp Mol Med 41: 67-76, 2009.
17. Eckerson HW, Wyte CM and La Du BN: The human serum paraoxonase/ arylesterase polymorphism. Am J Hum Genet 35: 1126-1138, 1983.
18. Park KH, Shin DG, Kim JR, Hong JH and Cho KH: The functional and compositional properties of lipoproteins are altered in patients with metabolic syndrome with increased cholesteryl ester transfer protein activity. Int J Mol Med 25: 129-136, 2010.
19. Lee H, Park JE, Choi I and Cho KH: Enhanced functional and structural properties of high-density lipoproteins from runners and wrestlers compared to throwers and lifters. BMB Rep 42: 605-610, 2009.
20. Park KH, Jang W, Kim KY, Kim JR and Cho KH: Fructated apolipoprotein A-I showed severe structural modification and loss of beneficial functions in lipid-free and lipid-bound state with acceleration of atherosclerosis and senescence. Biochem Biophys Res Commun 392: 295-300, 2010.
21. Zago V, Sanguinetti S, Brites F, Berg G, Verona J, Basilio F, Wikinski R and Schreier L: Impaired high density lipoprotein antioxidant activity in healthy postmenopausal women. Atherosclerosis 177: 203-210, 2004.
22. Deakin S, Moren X and James RW: Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis 179: 17-25, 2005.
23. 2. Clin Biochem 30: 221-225, 1997.
24. Mackness MI, Arrol S and Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286: 152-154, 1991.
25. Morton RE: Cholesteryl ester transfer protein and its plasma regulator: lipid transfer inhibitor protein. Curr Opin Lipidol 10: 321-327, 1999.
26. Bajnok L, Seres I, Varga Z, Jeges S, Peti A, Karanyi Z, Juhasz A, Csongradi E, Mezosi E, Nagy EV and Paragh G: Relationship of endogenous hyperleptinemia to serum paraoxonase 1, cholesteryl ester transfer protein, and lecithin cholesterol acyltransferase in obese individuals. Metabolism 56: 1542-1549, 2007.
27. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, Subbanagounder G, Faull KF, Reddy ST, Miller NE and Fogelman AM: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 41: 1481-1494, 2000.
28. Feng H and Li XA: Dysfunctional high-density lipoprotein. Curr Opin Endocrinol Diabetes Obes 16: 156-162, 2009.
29. Ji Y and Jonas A: Properties of an N-terminal proteolytic fragment of apolipoprotein AI in solution and in reconstituted high density lipoproteins. J Biol Chem 270: 11290-11297, 1995.
30. Cho KH, Park SH, Han JM, Kim HC, Chung YJ, Choi I and Kim JR: A point mutant of apolipoprotein A-I, V156K, exhibited potent anti-oxidant and anti-atherosclerotic activity in hypercholesterolemic C57BL/6 mice. Exp Mol Med 39: 160-169, 2007.